TCM
TRIB

Tamarack Capital Management’s Trinity Biotech TRIB Stock Holding History

Tamarack Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-25,000
Closed -$2.19M – 46
2014
Q4 		$2.19M Buy
+25,000
New +$2.15M 0.33% 35

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

Tamarack Capital Management's TRIB Position: Q1 2015 in Review

Tamarack Capital Management sold out of Trinity Biotech (TRIB) in Q1 2015, closing a stake of 25,000 shares — an estimated $2.19M sold.

Tamarack Capital Management first reported a position in TRIB in Q4 2014 and held it in 1 quarter. The position peaked at $2.19M in Q4 2014. 89 funds tracked by Wall St. Rank hold TRIB as of Q1 2015.

  • Tamarack Capital Management reported no remaining Trinity Biotech position as of Q1 2015 after selling out during the quarter.
  • Tamarack Capital Management sold 25,000 Trinity Biotech shares in Q1 2015, an estimated $2.19M.
  • Tamarack Capital Management first reported a position in Trinity Biotech in Q4 2014 and held it in 1 quarter.
  • Tamarack Capital Management's Trinity Biotech position peaked at $2.19M in Q4 2014.
  • 89 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2015.

Based on Tamarack Capital Management's 13F filing for Q1 2015, filed 11 May 2015.